Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on May 21, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Human Cell Line Optimization for Microfluidic Assay

Closed
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The contract involves optimizing human-derived brain microvascular endothelial cells, neurons, and astrocytes to support their use in a three-dimensional microfluidic blood-brain barrier model. This includes developing protocols and conducting functional testing to ensure the cells perform effectively within the assay system. The objective is to enhance the biological relevance and reliability of the 3D microfluidic model for blood-brain barrier research. Issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, this subcontract focuses on human cell line optimization for microfluidic assays. The work will be performed in Silver Spring, with responses due by June 12, 2026. The contract falls under the NAICS code 541610, which relates to administrative management and general management consulting services.

General Info

Optimize human brain cells for 3D microfluidic blood-brain barrier model, including testing protocols.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant SvcsView Agency

NAICS

541610

Place of Performance

Silver Spring, MD, USA

Set-Aside

NONE

Documents

This scope was carved out of FDA_5212026.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Development of 3D Human Blood Brain Barrier Formation Assay

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

subcontract

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Optimize human-derived brain microvascular endothelial cells, neurons, and astrocytes for use in a 3D microfluidic blood-brain barrier model, including protocol development and functional testing.

More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

Same awarding agency

NAICS: 541714
New
Federal
Human Hindbrain Organoid Functional Assay Services.
Solicitation # RFQ_CDR-2026-135968
The U.S. Food and Drug Administration, through the Center for Drug Evaluation and Research, intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services. This acquisition, conducted under FAR Part 12 as a commercial service, aims to support in vitro research on drug-induced effects on respiratory-relevant neural circuits. The scope of work includes the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

1 day ago

DEADLINE

in 5 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS